scholarly journals Dietary interventions for fetal growth restriction - therapeutic potential of dietary nitrate supplementation in pregnancy

2017 ◽  
Vol 595 (15) ◽  
pp. 5095-5102 ◽  
Author(s):  
Elizabeth Cottrell ◽  
Teresa Tropea ◽  
Laura Ormesher ◽  
Susan Greenwood ◽  
Mark Wareing ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Therapeutic Potential ◽  
Growth Restriction ◽  
Dietary Interventions ◽  
Dietary Nitrate ◽  
Nitrate Supplementation ◽  
In Pregnancy

The secrets of placental mosaicism: clinical observation of the full form of confined placental trisomy 22 and literature review

2020 ◽  
Author(s):  
I.V. Komarova, A.A. Nikiforenko, A.V. Fedunyak
Keyword(s):  
Prenatal Diagnosis ◽  
Literature Review ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Clinical Observation ◽  
Growth Restriction ◽  
Favorable Outcome ◽  
Full Form ◽  
Placental Mosaicism ◽  
In Pregnancy

Literature reports of placental mosaicism, including trisomy 22, were analyzed. The chance of correlation of placental aneuploidy with fetus aneuploidy, also the probability of complications in pregnancy and fetal growth restriction and postnatal patients growth in the cases of confined placental mosaicism, were demonstrated. The case of prenatal diagnosis of confined placental mosaicism of trisomy 22 with favorable outcome is presented. The necessity of cytogenic assay of amniocytes and fetal lymphocytes in the case of placental heteroploidy diagnosis was emphasized.

scholarly journals Non-targeted urinary metabolomics in pregnancy and associations with fetal growth restriction

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Chelsea M. Clinton ◽  
James R. Bain ◽  
Michael J. Muehlbauer ◽  
YuanYuan Li ◽  
Leping Li ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
In Pregnancy

T11.1 Association between stillbirth, fetal growth restriction and hypertensive diseases in pregnancy

2010 ◽  
Vol 1 ◽  
pp. S21
Author(s):  
Tony Odibo ◽  
Andre Francis ◽  
Alison Cahill ◽  
Roxanne Rampersad ◽  
George Macones ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Hypertensive Diseases ◽  
In Pregnancy

scholarly journals Maternal sirolimus therapy and fetal growth restriction

2021 ◽  
Vol 8 (2) ◽  
pp. 19-24
Author(s):  
Sangay Tshering ◽  
Namkha Dorji ◽  
Youden Sonam
Keyword(s):  
Case Report ◽  
Signaling Pathway ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Mtor Signaling ◽  
Growth Restriction ◽  
Mtor Signaling Pathway ◽  
Epigenetic Modulation ◽  
In Pregnancy

Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling pathway and epigenetic modulation. This case report adds to the paucity of literature on continued monotherapeutic maternal sirolimus in pregnancy and its adverse fetal effects.

scholarly journals Docosahexaenoic Acid Supplementation Early in Pregnancy May Prevent Deep Placentation Disorders

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Jorge A. Carvajal
Keyword(s):  
Preterm Birth ◽  
Docosahexaenoic Acid ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Preterm Labor ◽  
Growth Restriction ◽  
Premature Rupture Of Membranes ◽  
Premature Rupture ◽  
Preterm Premature Rupture ◽  
In Pregnancy

Uteroplacental ischemia may cause preterm birth, either due to preterm labor, preterm premature rupture of membranes, or medical indication (in the presence of preeclampsia or fetal growth restriction). Uteroplacental ischemia is the product of defective deep placentation, a failure of invasion, and transformation of the spiral arteries by the trophoblast. The failure of normal placentation generates a series of clinical abnormalities nowadays called “deep placentation disorders”; they include preeclampsia, fetal growth restriction, preterm labor, preterm premature rupture of membranes, in utero fetal death, and placental abruption. Early reports suggested that a LC-PUFAs (long chain polyunsaturated fatty acids) rich diet reduces the incidence of deep placentation disorders. Recent randomized controlled trials are inconsistent to show the benefit of docosahexaenoic acid (DHA) supplementation during pregnancy to prevent deep placentation disorders, but most of them showed that DHA supplementation was associated with lower risk of early preterm birth. We postulate that DHA supplementation, early in pregnancy, may reduce the incidence of deep placentation disorders. If our hypothesis is correct, DHA supplementation, early in pregnancy, will become a safe and effective strategy for primary prevention of highly relevant pregnancy diseases, such as preterm birth, preeclampsia, and fetal growth restriction.

scholarly journals 112: Urinary metabolomic profiles in pregnancy and association with fetal growth restriction

2019 ◽  
Vol 220 (1) ◽  
pp. S90-S91
Author(s):  
Chelsea M. Clinton ◽  
James R. Bain ◽  
Michael J. Muehlbauer ◽  
Sara K. O'Neal ◽  
Brenna L. Hughes ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document